Highlight
Among patients with esophageal or gastroesophageal junction adenocarcinoma who achieve pathological complete response (pCR) after neoadjuvant treatment, perioperative FLOT chemotherapy is associated with significantly improved overall and disease-free survival compared to CROSS chemoradiotherapy. Furthermore, FLOT yields a lower recurrence rate, with later recurrence onset and more heterogeneous patterns than CROSS. Subgroup analyses emphasize greater survival benefits of FLOT in patients with clinical node-negative or low nodal burden.
